{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:55:28Z","timestamp":1788566128869,"version":"build-2803163510"},"reference-count":64,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in inflammatory bowel disease (IBD) patients due to chronic inflammation and metabolic disturbances. However, reliable non-invasive biomarkers for MASLD prediction in this population are lacking. This study evaluated the predictive value of metabolic scores and lipid ratios for MASLD onset in IBD patients. Methods: An observational retrospective study was conducted on 358 IBD patients at the \u201cRenato Dulbecco\u201d Teaching Hospital in Catanzaro, Italy, in a period between 1 January 2021 and 31 December 2024. Clinical and laboratory data, including metabolic scores and lipid ratios, were analyzed using the chi-square and Kruskal\u2013Wallis tests as appropriate. Post hoc comparisons were conducted using Dunn\u2019s test. Receiver operating characteristic analysis assessed their predictive accuracy for MASLD. p &lt; 0.05 was considered significant. Results: IBD-MASLD patients had a significantly higher body mass index (BMI, 27 \u00b1 4 vs. 22 \u00b1 2 kg\/m2; p &lt; 0.001), waist circumference (100 \u00b1 11 vs. 85 \u00b1 4 cm; p &lt; 0.001), other anthropometric parameters, metabolic scores, and lipid ratios than IBD-only patients. The metabolic score for insulin resistance [METS-IR, area under curve (AUC = 0.754)] and waist circumference (AUC = 0.754) exhibited the highest predictive accuracy, followed by the lipid accumulation product (LAP, AUC = 0.737), BMI (AUC = 0.709), and triglyceride\/high-density lipoprotein (TG\/HDL, AUC = 0.701). Insulin resistance scores, including the homeostasis model assessment of insulin resistance (AUC = 0.680) and triglyceride-glucose index (AUC = 0.674), were of moderate predictive use. The visceral adiposity index (AUC = 0.664) and low-density lipoprotein\/high-density lipoprotein (AUC = 0.656) showed lower discriminative ability, while the fibrosis-4 index (AUC = 0.562) had the weakest diagnostic performance. Conclusions: Our findings suggest that MASLD in IBD is primarily driven by cardiometabolic dysfunction. The introduction of the METS-IR, LAP, and TG\/HDL into clinical assessments of IBD patients could prove useful in preventing liver and cardiovascular complications in this setting.<\/jats:p>","DOI":"10.3390\/jcm14092973","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T08:02:57Z","timestamp":1745568177000},"page":"2973","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-1524","authenticated-orcid":false,"given":"Ludovico","family":"Abenavoli","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7084-8264","authenticated-orcid":false,"given":"Giuseppe Guido Maria","family":"Scarlata","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6461-6563","authenticated-orcid":false,"given":"Massimo","family":"Borelli","sequence":"additional","affiliation":[{"name":"UMG School of PhD Programmes \u201cLife Sciences and Technologies\u201d, University \u201cMagna Graecia\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Suraci","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Marasco","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Imeneo","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Renato Dulbecco University Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-4644","authenticated-orcid":false,"given":"Rocco","family":"Spagnuolo","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-1046","authenticated-orcid":false,"given":"Francesco","family":"Luzza","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Shang","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","first-page":"S41","article-title":"Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Noureddin","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Spagnuolo, R., Larussa, T., Iannelli, C., Cosco, C., Nistic\u00f2, E., Manduci, E., Bruno, A., Boccuto, L., Abenavoli, L., and Luzza, F. (2020). COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina, 56.","DOI":"10.3390\/medicina56080407"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00384-024-04711-x","article-title":"Global, regional, and national burden of inflammatory bowel disease, 1990-2021: Insights from the global burden of disease 2021","volume":"39","author":"Lin","year":"2024","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17474124.2025.2464037","article-title":"Gut microbiota: The pathogenetic bridge between inflammatory bowel disease and metabolic-associated steatotic liver disease","volume":"19","author":"Scarlata","year":"2025","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.20517\/2394-5079.2023.134","article-title":"Dysmetabolic comorbidities and non-alcoholic fatty liver disease: A stairway to metabolic dysfunction-associated steatotic liver disease","volume":"10","author":"Colaci","year":"2024","journal-title":"Hepatoma Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cgh.2022.01.039","article-title":"Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors","volume":"21","author":"Calleja","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MCG.0000000000002079","article-title":"Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals with Type 2 Diabetes Mellitus","volume":"59","author":"Ahmadizar","year":"2025","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3350\/cmh.2017.0042","article-title":"Imaging evaluation of non-alcoholic fatty liver disease: Focused on quantification","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4292\/wjgpt.v7.i1.91","article-title":"Clinical applications, limitations and future role of transient elastography in the management of liver disease","volume":"7","author":"Chang","year":"2016","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e13034","DOI":"10.1002\/jgh3.13034","article-title":"Suboptimal reliability of FIB-4 and NAFLD-fibrosis scores for staging of liver fibrosis in general population","volume":"8","author":"Hazzan","year":"2024","journal-title":"JGH Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr. Obes. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Spagnuolo, R., Scarlata, G.G.M., Scarpellini, E., Boccuto, L., and Luzza, F. (2023). Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study. Medicina, 59.","DOI":"10.3390\/medicina59111935"},{"key":"ref_18","first-page":"74","article-title":"Can dysmetabolic comorbidities carry hepatic fat accumulation in patients with inflammatory bowel diseases?","volume":"71","author":"Abenavoli","year":"2024","journal-title":"Minerva Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Spagnuolo, R., Scarlata, G.G.M., Gambardella, M.L., Boccuto, L., M\u00e9ndez-S\u00e1nchez, N., and Luzza, F. (2024). Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study. Life, 14.","DOI":"10.3390\/life14101226"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/SGA.0000000000000461","article-title":"Ulcerative Colitis as an Independent Risk Factor for Hepatic Steatosis","volume":"43","author":"Mancina","year":"2020","journal-title":"Gastroenterol. Nurs."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","article-title":"Predicting the Crohn\u2019s disease activity index from the Harvey-Bradshaw Index","volume":"12","author":"Best","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","unstructured":"Weir, C.B., and Jan, A. (2025, March 10). BMI Classification Percentile And Cut Off Points. [Updated 26 June 2023], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541070\/."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kahn, H.S. (2005). The \u201clipid accumulation product\u201d performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison. BMC Cardiovasc. Disord., 5.","DOI":"10.1186\/1471-2261-5-26"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2337\/diacare.20.7.1087","article-title":"The homeostasis model in the San Antonio Heart Study","volume":"20","author":"Haffner","year":"1997","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-17-0883","article-title":"METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes","volume":"178","author":"Campos","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Baneu, P., V\u0103c\u0103rescu, C., Dr\u0103gan, S.R., Cirin, L., Laz\u0103r-H\u00f6cher, A.I., Cozgarea, A., Faur-Grigori, A.A., Cri\u0219an, S., Gai\u021b\u0103, D., and Luca, C.T. (2024). The Triglyceride\/HDL Ratio as a Surrogate Biomarker for Insulin Resistance. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071493"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12933-024-02392-y","article-title":"Diagnostic and prognostic value of triglyceride glucose index: A comprehensive evaluation of meta-analysis","volume":"23","author":"Nayak","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.metabol.2009.09.009","article-title":"Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis","volume":"59","author":"Tamada","year":"2010","journal-title":"Metabolism"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Blanco-Grau, A., Gabriel-Medina, P., Rodriguez-Algarra, F., Villena, Y., Lopez-Mart\u00ednez, R., August\u00edn, S., Pons, M., Cruz, L.M., Rando-Segura, A., and Enfedaque, B. (2021). Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics, 11.","DOI":"10.3390\/diagnostics11122236"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.C., and M\u00fcller, M. (2011). pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform., 12.","DOI":"10.1186\/1471-2105-12-77"},{"key":"ref_37","unstructured":"R Core Team (2025). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3748\/wjg.v30.i7.652","article-title":"Recent advances in age-related metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"He","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13098-022-00930-w","article-title":"Age patterns of nonalcoholic fatty liver disease incidence: Heterogeneous associations with metabolic changes","volume":"14","author":"Lin","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103702","DOI":"10.1016\/j.numecd.2024.07.019","article-title":"Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future","volume":"35","author":"Corrao","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"i2286","DOI":"10.1093\/ecco-jcc\/jjae190.1438","article-title":"P1264 Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with Inflammatory Bowel Disease (IBD). A prospective single-center study","volume":"19","author":"Pastras","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zou, H., Ma, X., Pan, W., and Xie, Y. (2024). Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population. Front. Nutr., 11.","DOI":"10.3389\/fnut.2024.1411802"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: A comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Capela, T.L., Silva, V.M., Freitas, M., Arieira, C., Gon\u00e7alves, T.C., de Castro, F.D., Magalh\u00e3es, J., and Cotter, J. (2023). Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: Usefulness of non-invasive steatosis predictive scores. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-02988-w"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/gutjnl-2024-331914","article-title":"Heavy arch: From inflammatory bowel diseases to metabolic disorders","volume":"73","author":"Adolph","year":"2024","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sun, J., Yan, C., Wen, J., Wang, F., Wu, H., and Xu, F. (2024). Association between different obesity patterns and the risk of NAFLD detected by transient elastography: A cross-sectional study. BMC Gastroenterol., 24.","DOI":"10.1186\/s12876-024-03303-x"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.jhep.2023.11.024","article-title":"Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease","volume":"80","author":"Chen","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e043952","DOI":"10.1136\/bmjopen-2020-043952","article-title":"Optimised anthropometric indices as predictive screening tools for metabolic syndrome in adults: A cross-sectional study","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Manent, J.I., Jover, A.M., Martinez, C.S., Tom\u00e1s-Gil, P., Mart\u00ed-Lliteras, P., and L\u00f3pez-Gonz\u00e1lez, \u00c1.A. (2023). Waist Circumference Is an Essential Factor in Predicting Insulin Resistance and Early Detection of Metabolic Syndrome in Adults. Nutrients, 15.","DOI":"10.3390\/nu15020257"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3345\/kjp.2019.00248","article-title":"Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity","volume":"62","author":"Demirhan","year":"2019","journal-title":"Korean J. Pediatr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12986-017-0206-2","article-title":"Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults","volume":"14","author":"Dai","year":"2017","journal-title":"Nutr. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-022-01636-8","article-title":"Diagnostic accuracy of the visceral adiposity index in patients with metabolic-associated fatty liver disease: A meta-analysis","volume":"21","author":"Yi","year":"2022","journal-title":"Lipids Health Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.numecd.2023.09.009","article-title":"Effect of CVAI on the incidence of MASLD compared to BMI in populations with different body types: A prospective cohort study in China","volume":"34","author":"Zhao","year":"2024","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.2147\/DMSO.S476398","article-title":"METS-IR, a Novel Simple Insulin Resistance Index, is Associated with NAFLD in Patients with Type 2 Diabetes Mellitus","volume":"17","author":"Ma","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12933-024-02334-8","article-title":"Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: Evidence from NHANES 2001\u20132018","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3350\/cmh.2022.0099","article-title":"The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12933-024-02263-6","article-title":"Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease","volume":"23","author":"Colantoni","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.jhep.2024.08.005","article-title":"Hs-CRP and HOMA-IR: Include them in the MASLD definition, or treat them as mediators between MASLD and atherosclerotic cardiovascular disease?","volume":"82","author":"Wan","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-024-02572-w","article-title":"Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: A cohort study of UK Biobank","volume":"24","author":"Qiao","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Montoro, J.I., Mart\u00ednez-S\u00e1nchez, M.A., Balaguer-Rom\u00e1n, A., Fern\u00e1ndez-Ruiz, V.E., Hern\u00e1ndez-Barcel\u00f3, J.E., Ferrer-G\u00f3mez, M., Frutos, M.D., N\u00fa\u00f1ez-S\u00e1nchez, M.\u00c1., Fern\u00e1ndez-Garc\u00eda, J.C., and Ramos-Molina, B. (2024). Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study. Nutrients, 16.","DOI":"10.3390\/nu16091310"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-021-01457-1","article-title":"LDL\/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: A 5-year longitudinal cohort study","volume":"20","author":"Zou","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ferraz-Amaro, I., Hern\u00e1ndez-Camba, A., Carrillo-Palau, M., Hern\u00e1ndez \u00c1lvarez-Buylla, N., de Vera-Gonz\u00e1lez, A., Gonz\u00e1lez-Delgado, A., Heras-Recuero, E., and Gonz\u00e1lez-Gay, M.\u00c1. (2024). Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216430"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41366-021-01015-w","article-title":"Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank","volume":"46","author":"Tavaglione","year":"2022","journal-title":"Int. J. Obes."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/2973\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:21:26Z","timestamp":1760030486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/9\/2973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14092973"],"URL":"https:\/\/doi.org\/10.3390\/jcm14092973","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}